0001437749-23-031425.txt : 20231113 0001437749-23-031425.hdr.sgml : 20231113 20231113091250 ACCESSION NUMBER: 0001437749-23-031425 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulse Biosciences, Inc. CENTRAL INDEX KEY: 0001625101 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 465696597 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37744 FILM NUMBER: 231395712 BUSINESS ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 510-906-4600 MAIL ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 FORMER COMPANY: FORMER CONFORMED NAME: Electroblate, Inc. DATE OF NAME CHANGE: 20141113 8-K 1 plse20231108_8k.htm FORM 8-K plse20231108_8k.htm
false 0001625101 0001625101 2023-11-13 2023-11-13
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): November 13, 2023
 
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3957 Point Eden Way 
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
 
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02
Results of Operations and Financial Condition.
 
On November 13, 2023, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter ended September 30, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
 
This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Number
Description
   
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PULSE BIOSCIENCES, INC.
  
     
     
Date: November 13, 2023
By:
/s/ Kevin P. Danahy
  
   
Kevin P. Danahy
  
   
President and Chief Executive Officer
(Principal Executive and Principal Financial Officer)
  
 
 
 EX-99.1 2 ex_594308.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED NOVEMBER 13, 2023 ex_594308.htm

Exhibit 99.1

 

Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

 

Pulse Biosciences will host Third Quarter 2023 Financial Results conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023

 

HAYWARD, Calif. [Business Wire] – November 13, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023.

 

Recent Business Highlights

 

●

 Advanced feasibility and preclinical studies for the cardiac ablation clamp and catheter programs, and expect to file an FDA 510(k) submission for the cardiac surgical clamp between December and end of first quarter 2024 and to commence the initial, Pulse Biosciences, first-in-human, CellFX nsPFA circumferential cardiac ablation catheter procedure within a window of time commencing between December 2023 and end of first quarter 2024
 

●

 Appointed renowned cardiothoracic surgeon Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery to lead the clinical strategy and contribute to the development of the product portfolio
 

●

 Presentation by electrophysiologist key opinion leader Dr. Usman Siddiqui at the Global EP Summit 2023 featured the CellFX nsPFA circumferential catheter system and detailed both the utility of the novel energy modality and its potential impact on the treatment of atrial fibrillation
  ● Completed treatment of 21 subjects in the thyroid clinical feasibility study. Initial group was treated percutaneously with initial parameters in June 2023 with evaluations at 30, 90, 180, and 360 days post treatment. An additional group was started on November 7, 2023 with the goal of optimizing treatment parameters.

 

●

 Two poster presentations at the American Thyroid Association 2023 Annual Meeting suggest the percutaneous electrode delivery of CellFX nsPFA may be a safe and effective method for treating benign thyroid nodules, as supported by data from the first prospective clinical feasibility study of the technology

 

“We made tremendous progress advancing our cardiac device development in the third quarter. In the lab, our CellFX nsPFA technology continues to demonstrate the potential to revolutionize the treatment of atrial fibrillation. In the clinic, CellFX nsPFA is demonstrating the ability to safely and effectively treat benign thyroid nodules, and at the podium, we are pleased to be seeing increasing external validation of our technology from KOLs at various scientific meetings,” said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. “With the addition of another renowned cardiothoracic surgeon, Dr. Niv Ad, to our leadership team, we are on track to file a 510(k) submission for clearance for our cardiac ablation clamp and initiate the cardiac ablation catheter first-in-human study between December 2023 and end of first quarter 2024.”

 

Third Quarter 2023 Results

Total GAAP cost and expenses, representing cost of revenues, research and development, sales and marketing, and general and administrative expenses, for the three months ended September 30, 2023, were $11.3 million compared to $18.0 million for the prior year period. Non-GAAP cost and expenses for the three months ended September 30, 2023, were $9.2 million compared to $16.8 million for the prior year period. The decrease in costs and expenses compared to the prior year period was driven by the prior headcount reduction and restructuring and the $7.2 million inventory reserve related to the dermatology business in the third quarter 2022, partially offset by an increase in research and development expenses to support advancement of our CellFX nsPFA cardiology devices.

 

GAAP net loss for the three months ended September 30, 2023 was ($10.6) million compared to ($18.0) million for the three months ended September 30, 2022. Non-GAAP net loss for the three months ended September 30, 2023 was ($8.5) million compared to ($16.8) million for the three months ended September 30, 2022.

 

Cash and cash equivalents totaled $50.4 million as of September 30, 2023, compared to $69.2 million as of September 30, 2022 and $58.7 million as of June 30, 2023. Cash used in the third quarter of 2023 was $8.7 million compared to $10.6 million in the same period in the prior year and $10.0 million used in the second quarter of 2023.

 

Reconciliations of GAAP to non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

 

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call today, November 13, 2023, beginning at 9:00am PT. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

 

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where CellFX nsPFA could have a profound positive impact on healthcare for both patients and providers.

 

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

 

Non-GAAP Financial Measures

In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization and restructuring charges. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.

 

 
 

 

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:

 

Non-cash expenses for stock-based compensation.  The Company has excluded the effect of stock-based compensation expenses in calculating the Company’s non-GAAP cost and expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of time-based and performance-based options, such as options that vest as a result of the Company’s market capitalization. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons from period to period.

 

Depreciation and amortization.  The Company has excluded depreciation and amortization expense in calculating its non-GAAP cost and expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.

 

Restructuring charges.  The Company has excluded restructuring charges in calculating its non-GAAP cost and expenses and net loss measures. Restructuring programs involve discrete initiatives designed to improve operating efficiencies and include employee termination, contract termination, and other exit costs associated with the restructuring program. The Company believes that excluding discrete restructuring charges allows for better comparisons from period to period.

 

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, such as advancement of its cardiac clamp through the appropriate FDA regulatory path and possible initiation of a first-in-human safety feasibility study of its CellFX nsPFA cardiac ablation catheter system, statements concerning the Company’s future regulatory strategies and possible government clearances and approvals, statements concerning customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation and benign thyroid nodules, statements about the Company’s future financing opportunities and operating expenses, and Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s CellFX nsPFA technology will become a disruptive treatment option for treating cardiac arrhythmias, benign thyroid nodules or any other medical condition and whether future clinical studies will show the CellFX System is safe and effective to treat atrial fibrillation, benign thyroid nodules or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

 

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

or
Gilmartin Group
Philip Trip Taylor

415.937.5406
philip@gilmartinir.com

 
 

 

PULSE BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

 

   

September 30,

    

December 31,

  
   

2023

    

2022

  

ASSETS

                

Current assets:

                

Cash and cash equivalents

   $ 50,386     $ 61,139  

Prepaid expenses and other current assets

     1,237       1,008  

Total current assets

     51,623       62,147  
                 

Property and equipment, net

     1,648       1,961  

Intangible assets, net

     2,052       2,551  

Goodwill

     2,791       2,791  

Right-of-use assets

     7,466       8,062  

Other assets

     365       365  

Total assets

   $ 65,945     $ 77,877  
                 

LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable

   $ 1,412     $ 1,573  

Accrued expenses

     3,004       2,595  

Lease liability, current

     1,016       896  

Related party note payable, current

     —       917  

Total current liabilities

     5,432       5,981  
                 

Lease liability, less current

     8,368       9,144  

Related party note payable, less current

     —       65,000  

Total liabilities

     13,800       80,125  
                 

Stockholders’ equity:

                

Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding

     —       —  

Common stock, $0.001 par value; authorized – 500,000 shares; issued and outstanding – 54,991 shares and 37,235 shares at September 30, 2023 and December 31, 2022, respectively

     55       37  

Additional paid-in capital

     377,072       292,420  

Accumulated other comprehensive income (loss)

     —       —  

Accumulated deficit

     (324,982 )     (294,705 )

Total stockholders’ equity (deficit)

     52,145       (2,248 )

Total liabilities and stockholders’ equity

   $ 65,945     $ 77,877  

 

 
 

 

PULSE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)

 

   

Three-Month Periods Ended

    

Nine-Month Periods Ended

  
   

September 30,

    

September 30,

  
      2023*       2022       2023*       2022  

Revenues:

                                

Product revenues

   $ —     $ —     $ —     $ 709  

Total revenues

     —       —       —       709  

Cost and expenses:

                                

Cost of revenues

     —       8,400       —       10,653  

Research and development

     7,472       4,517       19,998       16,744  

Sales and marketing

     —       2,020       —       11,251  

General and administrative

     3,780       3,088       11,043       11,373  

Total cost and expenses

     11,252       18,025       31,041       50,021  

Loss from operations

     (11,252 )     (18,025 )     (31,041 )     (49,312 )

Other income (expense):

                                

Interest income (expense), net

     686       (14 )     764       4  

Total other income (expense)

     686       (14 )     764       4  

Net loss

     (10,566 )     (18,039 )     (30,277 )     (49,308 )

Other comprehensive gain (loss):

                                

Unrealized gain (loss) on available-for-sale securities

     —       —       —       —  

Comprehensive loss

   $ (10,566 )   $ (18,039 )   $ (30,277 )   $ (49,308 )

Net loss per share:

                                

Basic and diluted net loss per share

   $ (0.19 )   $ (0.49 )   $ (0.66 )   $ (1.50 )

Weighted average shares used to compute net loss per common share — basic and diluted

     54,923       37,158       45,672       32,825  
                                 
                                 
                                 
   

Three-Month Periods Ended

    

Nine-Month Periods Ended

  
   

September 30,

    

September 30,

  

Stock Based Compensation Expense:

     2023*       2022       2023*       2022  

Cost of revenues

   $ —     $ 24     $ —     $ 204  

Research and development

     982       287       1,758       1,240  

Sales and marketing

     —       (44 )     —       772  

General and administrative

     816       456       2,079       2,227  

Total stock-based compensation expense

   $ 1,798     $ 723     $ 3,837     $ 4,443  
                                 

*For the three and nine month periods ended September 30, 2023, the Company reclassified certain expenses as a result of the shift in focus from dermatology to cardiology. Expenses previously included in Cost of Revenues are now recorded as a part of Research and Development, and expenses previously included in Sales and Marketing are now recorded as a part of General and Administrative.

  

 

 
 

 

PULSE BIOSCIENCES, INC.

Consolidated Revenue Financial Highlights

(In thousands)

(Unaudited)

 

   

Three-Month Periods Ended

    

Nine-Month Periods Ended

  
   

September 30,

    

September 30,

  
   

2023

    

2022

    

2023

    

2022

  

Revenue by category:

                                                                

Systems

   $ —       0 %   $ —       —     $ —       0 %   $ 576       81 %

Cycle units

     —       0 %     —       —       —       0 %     133       19 %

Total revenue

   $ —       0 %   $ —       —     $ —       0 %   $ 709       100 %
                                                                 

Revenue by geography:

                                                                

North America

   $ —       0 %   $ —       —     $ —       0 %   $ 526       74 %

Rest of World

     —       0 %     —       —       —       0 %     183       26 %

Total revenue

   $ —       0 %   $ —       —     $ —       0 %   $ 709       100 %

 

 
 

 

Reconciliation of GAAP to Non-GAAP Financial Measures

The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures:

(In thousands)

(Unaudited)

 

   

Three-Month Periods Ended

    

Nine-Month Periods Ended

  
   

September 30,

    

September 30,

  
   

2023

    

2022

    

2023

    

2022

  

Reconciliation of GAAP to non-GAAP Cost of revenues:

                                

GAAP Cost of revenues

   $ —     $ 8,400     $ —     $ 10,653  

Less: Stock-based compensation expense

     —       (24 )     —       (204 )

Less: Depreciation and amortization

     —       (5 )     —       (14 )

Less: Restructuring

     —       (27 )     —       (43 )

Non-GAAP Cost of revenues

   $ —     $ 8,344     $ —     $ 10,392  
                                 

Reconciliation of GAAP to non-GAAP Research and development:

                                

GAAP Research and development

   $ 7,472     $ 4,517     $ 19,998     $ 16,744  

Less: Stock-based compensation expense

     (982 )     (287 )     (1,758 )     (1,240 )

Less: Depreciation and amortization

     (55 )     (75 )     (172 )     (203 )

Less: Restructuring

     —       (54 )     (38 )     (177 )

Non-GAAP Research and development

   $ 6,435     $ 4,101     $ 18,030     $ 15,124  
                                 

Reconciliation of GAAP to non-GAAP Sales and marketing:

                                

GAAP Sales and marketing

   $ —     $ 2,020     $ —     $ 11,251  

Less: Stock-based compensation expense

     —       44       —       (772 )

Less: Depreciation and amortization

     —       (15 )     —       (43 )

Less: Restructuring

     —       (95 )     —       (598 )

Non-GAAP Sales and marketing

   $ —     $ 1,954     $ —     $ 9,838  
                                 

Reconciliation of GAAP to non-GAAP General and administrative:

                                

GAAP General and administrative

   $ 3,780     $ 3,088     $ 11,043     $ 11,373  

Less: Stock-based compensation expense

     (816 )     (456 )     (2,079 )     (2,227 )

Less: Depreciation and amortization

     (242 )     (244 )     (730 )     (758 )

Less: Restructuring

     —       (22 )     (5 )     (60 )

Non-GAAP General and administrative

   $ 2,722     $ 2,366     $ 8,229     $ 8,328  
                                 

Reconciliation of GAAP to non-GAAP Cost and expenses:

                                

GAAP Cost and expenses

   $ 11,252     $ 18,025     $ 31,041     $ 50,021  

Less: Stock-based compensation expense

     (1,798 )     (723 )     (3,837 )     (4,443 )

Less: Depreciation and amortization

     (297 )     (339 )     (902 )     (1,018 )

Less: Restructuring

     —       (198 )     (43 )     (878 )

Non-GAAP Cost and expenses

   $ 9,157     $ 16,765     $ 26,259     $ 43,682  
                                 

Reconciliation of GAAP to non-GAAP Net loss:

                                

GAAP Net loss

   $ (10,566 )   $ (18,039 )   $ (30,277 )   $ (49,308 )

Add: Stock-based compensation expense

     1,798       723       3,837       4,443  

Add: Depreciation and amortization

     297       339       902       1,018  

Add: Restructuring

     —       198       43       878  

Non-GAAP Net loss

   $ (8,471 )   $ (16,779 )   $ (25,495 )   $ (42,969 )

 

 
 EX-101.SCH 3 plse-20231113.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 plse-20231113_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 plse-20231113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 plse-20231113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 13, 2023
Document Information [Line Items]  
Entity, Registrant Name Pulse Biosciences, Inc.
Document, Type 8-K
Document, Period End Date Nov. 13, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37744
Entity, Tax Identification Number 46-5696597
Entity, Address, Address Line One 3957 Point Eden Way 
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 906-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol PLSE
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001625101
XML 8 plse20231108_8k_htm.xml IDEA: XBRL DOCUMENT 0001625101 2023-11-13 2023-11-13 false 0001625101 8-K 2023-11-13 Pulse Biosciences, Inc. DE 001-37744 46-5696597 3957 Point Eden Way  Hayward CA 94545 510 906-4600 false false false false Common stock PLSE NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.plse.com/20231113/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports plse-20231113.xsd plse-20231113_def.xml plse-20231113_lab.xml plse-20231113_pre.xml plse20231108_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "plse20231108_8k.htm": { "nsprefix": "plse", "nsuri": "http://www.plse.com/20231113", "dts": { "schema": { "local": [ "plse-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "plse-20231113_def.xml" ] }, "labelLink": { "local": [ "plse-20231113_lab.xml" ] }, "presentationLink": { "local": [ "plse-20231113_pre.xml" ] }, "inline": { "local": [ "plse20231108_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.plse.com/20231113/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20238K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "plse20231108_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20238K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "plse20231108_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.plse.com/20231113/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001437749-23-031425-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-031425-xbrl.zip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